In a closely watched pharmaceutical patent dispute, UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG secured a consent judgment and injunction against Mylan NV before the Vermont District Court (Case No. 2:22-cv-00216), closing on July 1, 2024 after 567 days of litigation. The case centered on four U.S. patents—US8246980B2, US8246979B2, US10130589B2, and US10350174B2—covering rotigotine transdermal delivery systems and the use of polyvinylpyrrolidone to stabilize the drug’s non-crystalline form. The negotiated settlement, presided over by Chief Judge Christina Reiss, resulted in stipulated entry of judgment and injunctive relief, effectively blocking Mylan’s competing product.

This outcome carries significant weight for pharmaceutical IP practitioners navigating generic-entry challenges to specialty transdermal drug products. The consent judgment model—where parties agree to injunctive terms rather than litigate through trial—reflects a well-established Hatch-Waxman strategy that brand-name manufacturers use to protect complex formulation patents. R&D teams developing transdermal delivery platforms, and in-house counsel monitoring generic pipeline threats to neurological drug patents, should study this case closely for its strategic and FTO implications.

Case Overview

The Parties

The Patents at Issue

The four patents at issue cover the rotigotine transdermal patch system—a skin patch that continuously delivers rotigotine, a dopamine agonist used to treat Parkinson’s disease and restless legs syndrome. Key claims protect the use of polyvinylpyrrolidone (PVP) as a stabilizing excipient that keeps rotigotine in its amorphous (non-crystalline) form within the patch matrix, preventing drug crystallization that would reduce efficacy. Additional claims cover the transdermal delivery system architecture itself, including the formulation and methods of administering rotigotine through the skin.

• • US8246980B2
• • US8246979B2
• • US10130589B2
• • US10350174B2

Legal Representation

Plaintiff Counsel: Covington & Burling LLP; Dinse PC (lead: Alexa R. Hansen , Esq.)
Defendant Counsel: Katten Muchin Rosenman LLP; Plante & Hanley PC (lead: Christopher W. West , Esq.)

Litigation Timeline & Procedural History

The case was filed on December 12, 2022 in the U.S. District Court for the District of Vermont, an uncommon venue for Hatch-Waxman pharmaceutical litigation, which typically concentrates in Delaware or New Jersey. Vermont’s selection likely reflects the presence of Mylan Technologies Inc.—a manufacturing subsidiary historically based in St. Albans, Vermont—giving the court personal jurisdiction over the defendant’s operations. As a first-instance district court matter, the case was handled at the trial level under Chief Judge Christina Reiss, meaning all substantive legal determinations would occur here prior to any potential Federal Circuit appeal.

The case ran for 567 days—approximately 19 months—before closing on July 1, 2024. This duration is consistent with complex pharmaceutical patent litigation that proceeds through claim construction and discovery before settling, but falls short of a full bench trial. Termination via consent judgment is a hallmark Hatch-Waxman resolution: rather than face an adverse infringement finding at trial, Mylan agreed to stipulated injunctive relief, effectively conceding that its generic product would infringe the asserted UCB/LTS Lohmann patents. The settlement agreement underlying the consent judgment likely includes negotiated commercial terms, such as a future generic launch date, that are not publicly disclosed in the court record.

The Verdict & Legal Analysis

Outcome

The Vermont District Court entered a consent judgment and injunction in favor of UCB Pharma GmbH, UCB Inc., and LTS Lohmann Therapie-Systeme AG against Mylan Technologies Inc., pursuant to a negotiated settlement agreement executed by the parties. The injunction bars Mylan from commercializing its proposed rotigotine transdermal product in violation of the asserted patents. No monetary damages were publicly adjudicated, as the resolution was structured as a stipulated judgment rather than a litigated merits determination.

Verdict Cause Analysis

The infringement action was resolved through consent judgment, reflecting the following key legal and strategic dynamics:

• All four asserted patents—US8246980B2, US8246979B2, US10130589B2, and US10350174B2—survived the litigation without invalidation, preserving UCB and LTS Lohmann’s exclusivity position over the rotigotine transdermal platform.
• Mylan’s consent to entry of injunctive relief signals that no viable non-infringement or invalidity defense was sufficiently strong to justify proceeding to trial, a common calculus in Hatch-Waxman litigation where generic manufacturers weigh litigation risk against negotiated entry dates.
• The transdermal delivery mechanism and PVP-stabilized amorphous rotigotine formulation claims were central to the infringement theory, and Mylan’s inability to design around these claims likely drove the settlement outcome.
• The Basis of Termination as a Consent Judgment means no claim construction ruling or invalidity finding was issued, leaving the patent claims intact and fully enforceable against other potential generic challengers in parallel or future ANDA proceedings.

Legal Significance

1. 1. Because the case terminated by consent judgment with no invalidity ruling, all four UCB/LTS Lohmann rotigotine patents remain presumptively valid and enforceable, strengthening their deterrent effect against other ANDA filers for rotigotine transdermal products.
2. 2. The absence of a public claim construction order from this litigation means that future defendants—or the same parties in post-grant proceedings—will face an open field in interpreting claims relating to PVP stabilization of amorphous rotigotine, preserving both risk and opportunity for challengers at the USPTO.
3. 3. Vermont District Court’s role as a Hatch-Waxman venue is reinforced by this case, underscoring that brand manufacturers can and do bring infringement actions in jurisdictions tied to a generic manufacturer’s physical operations, which may influence future venue strategy in pharmaceutical patent disputes.

Strategic Takeaways

For Patent Attorneys:

• When representing generic manufacturers in Hatch-Waxman litigation, conduct rigorous early case assessment of invalidity positions—Mylan’s consent to injunction suggests that its invalidity and non-infringement arguments were not strong enough to proceed to trial, a costly outcome that earlier IPR or PGR filings might have altered.
• Consent judgment structures can be strategically valuable for brand-name plaintiffs: they preserve patent validity, create public record of injunctive scope, and avoid the risk of an adverse claim construction ruling that could weaken the patent against other infringers.
• Assess venue strategy at the outset of Hatch-Waxman cases—UCB’s choice of Vermont, tied to Mylan Technologies’ manufacturing presence, demonstrates how plaintiffs can secure jurisdiction in non-traditional venues that may offer procedural advantages or scheduling benefits.
• Review the full patent family underlying rotigotine transdermal products (US8246980B2, US8246979B2, US10130589B2, US10350174B2) for claim mapping against any new transdermal dopamine agonist formulation, as these claims have now survived litigation unchallenged by Mylan.

For IP Professionals:

• In-house IP teams at generic pharmaceutical companies should prioritize early inter partes review (IPR) petitions against formulation patents of this type before ANDA filing triggers litigation, as post-filing challenges become strategically more difficult once an injunction consent framework is being negotiated.
• Brand-side IP portfolios in the transdermal drug delivery space should be audited to ensure that PVP-stabilization and amorphous-form delivery system claims are covered by layered continuation and divisional filings, as UCB and LTS Lohmann’s multi-patent assertion strategy effectively created a formidable blocking position.

For R&D Teams:

• R&D teams developing transdermal formulations for dopamine agonists or other CNS compounds should conduct Freedom-to-Operate analysis against the UCB/LTS Lohmann rotigotine patent family before selecting excipients such as polyvinylpyrrolidone, as claims covering PVP-stabilized amorphous drug forms remain fully enforceable following this litigation.
• Engineering teams working on transdermal delivery systems should explore alternative polymer stabilizers and crystallization-inhibition strategies as design-around options, and document these design choices early to build a strong FTO record that distinguishes from the asserted claims in US10130589B2 and US10350174B2.